Published in Mol Imaging Biol on September 21, 2006
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (2010) 2.21
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A (2011) 1.16
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging (2008) 1.08
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des (2008) 1.00
Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev (2008) 0.98
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer Biother Radiopharm (2008) 0.95
2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med (2009) 0.90
Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol (2008) 0.89
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. EJNMMI Res (2015) 0.88
Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res (2013) 0.87
The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg (2009) 0.86
Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release (2010) 0.82
Broadening the scope of image-guided radiotherapy (IGRT). Acta Oncol (2008) 0.81
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med (2010) 0.81
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol (2010) 0.77
What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging (2008) 0.77
Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. Oncogene (2017) 0.75
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA. Biomed Res Int (2013) 0.75
Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. Mol Cancer Ther (2009) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol (2011) 0.75
Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry. Biomed Res Int (2015) 0.75
In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy. PLoS One (2017) 0.75
Non-standard PET radionuclides: time to get ready for new clinical PET strategies. Eur J Nucl Med Mol Imaging (2007) 0.75
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 5.48
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Single-particle electron cryo-microscopy: towards atomic resolution. Q Rev Biophys (2000) 4.86
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Transplacental haemorrhage. Br J Haematol (1966) 3.02
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Caesarean scar pregnancy. BJOG (2007) 2.77
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res (1996) 2.22
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Survey of the needs of patients with spinal cord injury: impact and priority for improvement in hand function in tetraplegics. Spinal Cord (2004) 1.89
Immunological responses in pregnancy and survival of fetal homograft. Br Med J (1972) 1.86
Dose of anti-D gamma-globulin in prevention of Rh-haemolytic disease of the newborn. Br Med J (1966) 1.79
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Heterogeneous fatty acylation of Src family kinases with polyunsaturated fatty acids regulates raft localization and signal transduction. J Biol Chem (2001) 1.63
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Drilling the posterior wall of the petrous pyramid: a microneurosurgical anatomical study. J Neurosurg (1993) 1.57
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Depression of cellular immunity in pregnancy due to a serum factor. Br Med J (1973) 1.54
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
"Food allergy": Fact or Fiction? Lancet (1978) 1.44
Fetal penile length. Ultrasound Obstet Gynecol (2000) 1.43
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Frequency-distribution curve of uric acid in the general population. Lancet (1966) 1.42
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
A much misunderstood caduceus and the case for an aesculapion. Lancet (1999) 1.40
Estimation of fetal lung volume using enhanced 3-dimensional ultrasound: a new method and first result. Br J Obstet Gynaecol (1996) 1.40
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1999) 1.40
Oncologist's role critical to clinical trial enrollment. J Natl Cancer Inst (2000) 1.38
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (2002) 1.36
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
On the behavior of a capillary surface in a wedge. Proc Natl Acad Sci U S A (1969) 1.34
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia (2011) 1.30
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease? Int Arch Allergy Appl Immunol (1990) 1.26
Flecainide in the treatment of fetal tachycardias. Br Heart J (1991) 1.26
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
Surveys identify barriers to participation in clinical trials. J Natl Cancer Inst (2000) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res (1999) 1.24
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Plasma exchange in myasthenia gravis. Lancet (1977) 1.23
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A (2001) 1.22
Spontaneous abortion and fetal abnormality in subsequent pregnancy. Br Med J (1978) 1.22
Hydrocarbon exposure and glomerulonephritis. Clin Nephrol (1980) 1.22
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
Semiautomated radiosynthesis and biological evaluation of [18F]FEAU: a novel PET imaging agent for HSV1-tk/sr39tk reporter gene expression. Mol Imaging Biol (2007) 1.21
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid (2001) 1.17
The small GTPase Rab4A interacts with the central region of cytoplasmic dynein light intermediate chain-1. Biochem Biophys Res Commun (2001) 1.17
Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther (2002) 1.16
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer (2000) 1.15
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
Cooperative atom-light interaction in a blockaded Rydberg ensemble. Phys Rev Lett (2010) 1.15
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med (1985) 1.14
Transabdominal chorionic villus sampling. Lancet (1986) 1.14